HMGCR and metabolic syndrome: Rosuvastatin calcium tablets, which served as an oral 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitor, were extensively employed for the treatment of dyslipidemia, especially in elderly patients with coronary heart disease complicated by hyperlipidemia [1, 2].